WALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious ...
WALTHAM, Mass.–(BUSINESS WIRE)–Morphic Holding, Inc. (“Morphic”), a biopharmaceutical company discovering and developing oral small-molecule integrin therapeutics, today announced the closing of its ...
Since Friday, Morphic Therapeutic MORF shares have plunged from $47.92 to $26.25 after the company announced the publication of an abstract discussing new EMERALD-1 phase 2a primary results at United ...
Filed first IND of an oral integrin drug candidate, MORF-057, generated by Morphic’s MInT Platform and initiated first clinical study of MORF-057 in healthy volunteers in Phase 1 clinical trial of ...
WALTHAM, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious ...
Monday, Eli Lilly And Co (NYSE:LLY) agreed to acquire Morphic Holding Inc (NASDAQ:MORF) for $57 per share in cash, an aggregate of approximately $3.2 billion. Morphic is a biopharmaceutical company ...
A company developing therapies around a family of receptors that control a wide variety of cellular processes has raised a new Series B funding round. Waltham, Massachusetts-based Morphic Therapeutic ...
BOSTON--(BUSINESS WIRE)--Morphic Medical, creator of the world’s first medical device designed to target the underlying cause of type 2 diabetes, today announced the addition of James Reinstein, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results